New quinazoline sulfonamide derivatives as potential anticancer agents: Identifying a promising hit with dual EGFR/VEGFR-2 inhibitory and radiosensitizing activity.
ADMET
Anticancer
Quinazoline
Sulfonamide
Tyrosine kinase
Journal
Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
02
05
2023
revised:
14
07
2023
accepted:
14
08
2023
medline:
18
9
2023
pubmed:
24
8
2023
entrez:
23
8
2023
Statut:
ppublish
Résumé
Herein, we report the synthesis of a series of new quinazoline sulfonamide conjugates 2-16 and their evaluation as potential anticancer agents via dual targeting of EGFR
Identifiants
pubmed: 37611529
pii: S0045-2068(23)00452-2
doi: 10.1016/j.bioorg.2023.106791
pii:
doi:
Substances chimiques
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Protein Kinase Inhibitors
0
Antineoplastic Agents
0
Sulfanilamide
21240MF57M
EGFR protein, human
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106791Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.